( August 27, 2026, 2:26 PM EDT) -- NEW HAVEN, Conn. — Novo Nordisk Inc., facing an insulin XE "insulin" pen product liability action filed by a hospital system, asks a federal court to certify orders that “involve two controlling questions of Connecticut law that will materially advance the ultimate resolution of this case” to the Second Circuit U.S. Court of Appeals while its motion for reconsideration of one of those orders is pending....